Core Insights - Centene reported $46.62 billion in revenue for Q1 2025, a 15.4% year-over-year increase, with an EPS of $2.90 compared to $2.26 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company delivered a revenue surprise of +7.24% and an EPS surprise of +22.88% compared to analyst expectations [1] Financial Performance Metrics - Total Medical Health Benefits loss ratio was 87.1%, better than the estimated 87.9% [4] - Membership in High Acuity Medicaid stood at 1.59 million, matching analyst estimates [4] - Medicaid membership reached 12.96 million, slightly above the 12.94 million estimate [4] - SG&A Expense Ratio was 7.9%, lower than the estimated 8.4% [4] - Premium and service revenues totaled $42.49 billion, exceeding the $40.12 billion estimate, reflecting a 16.9% year-over-year increase [4] - Premium revenues were $41.71 billion, surpassing the $39.35 billion estimate, marking a 17.4% year-over-year change [4] - Service revenues were $777 million, slightly above the $768.54 million estimate, but a 3.8% decrease year-over-year [4] - Premium tax revenues were $4.13 billion, exceeding the $3.52 billion estimate, with a 1.5% year-over-year increase [4] - Commercial premium and service revenues reached $10.15 billion, significantly above the $9.04 billion estimate, representing a 30.9% year-over-year increase [4] - Medicare premium and service revenues were $8.76 billion, exceeding the $8.54 billion estimate, with a 47.6% year-over-year increase [4] - Medicaid premium and service revenues totaled $22.30 billion, above the $21.45 billion estimate, reflecting a 3.9% year-over-year increase [4] - Other premium and service revenues were $1.28 billion, exceeding the $1.22 billion estimate, with a 7.6% year-over-year increase [4] Stock Performance - Centene's shares returned +2.2% over the past month, contrasting with the Zacks S&P 500 composite's -4.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Viewpoint - Molina Healthcare Inc. reported strong first-quarter 2025 results, with adjusted EPS of $6.08, exceeding estimates and showing a year-over-year growth of 6.1% [1][2] Financial Performance - Total revenues reached $11.15 billion, reflecting a 12.2% year-over-year increase and slightly surpassing consensus estimates [1][3] - Premium revenues amounted to $10.63 billion, an 11.8% increase year over year, driven by contract wins, buyouts, and rate hikes, although partially offset by Medicaid redeterminations [3][4] - Total operating expenses were $10.7 billion, up 12.7% year over year, primarily due to rising medical care costs and higher administrative expenses [5][6] Membership and Income - Total membership increased by 0.4% year over year to approximately 5.8 million, although it fell short of consensus estimates by 3.3% [4] - Adjusted net income decreased by 0.3% year over year to $333 million [6] Financial Position - As of March 31, 2025, cash and cash equivalents rose to $4.9 billion from $4.7 billion at the end of 2024, while total assets increased to $16.4 billion [7] - Long-term debt increased to $3.6 billion from $2.9 billion at the end of 2024 [7][8] Guidance - The company reaffirmed its 2025 guidance, expecting premium revenues of around $42 billion, indicating a 9% improvement from 2024 [9] - Adjusted EPS is projected to be a minimum of $24.50, reflecting an 8% increase from the previous year [9][10]

MILWAUKEE, April 24, 2025 /PRNewswire/ -- Ademi & Fruchter LLP is investigating possible securities fraud claims against UnitedHealth (NYSE: UNH). The investigation results from inaccurate statements UnitedHealth made regarding its business operations and prospects.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.The investigation focuses on UnitedHealth's recent revisions ...

For the quarter ended March 2025, Molina (MOH) reported revenue of $11.15 billion, up 12.2% over the same period last year. EPS came in at $6.08, compared to $5.73 in the year-ago quarter. The reported revenue represents a surprise of +0.24% over the Zacks Consensus Estimate of $11.12 billion. With the consensus EPS estimate being $5.86, the EPS surprise was +3.75%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of UnitedHealth Group due to allegations of materially misleading business information [1] Group 1: Investigation and Legal Action - Shareholders who purchased UnitedHealth securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 2: Stock Performance and Earnings Report - UnitedHealth's stock fell 22.3% on April 17, 2025, after earnings fell short of Wall Street's expectations, primarily due to issues in its Medicare business [3] - The company substantially downgraded its projected results for 2025, citing problems in its Medicare operations [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]

On this news, UnitedHealth's stock fell 22.3% on April 17, 2025 WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions a ...

Core Viewpoint - Elevance Health, Inc. reported strong first-quarter 2025 results with adjusted EPS of $11.97, exceeding estimates and showing a year-over-year increase of 10.5% [1][2] Financial Performance - Operating revenues reached $48.8 billion, a 15.4% increase year over year, surpassing consensus estimates by 6% [1][4] - Premiums rose 14.5% year over year to $40.9 billion, exceeding the consensus mark of $38.7 billion [4] - Product revenues increased by 29.1% year over year to $5.8 billion, also beating estimates [4] - Net investment income grew 26.9% year over year to $590 million, surpassing the consensus of $461.3 million [4] - Total expenses were $46.1 billion, up 16.3% year over year, higher than estimates due to increased benefit expenses and operating costs [5] Membership and Operational Update - Medical membership stood at approximately 45.8 million, a 0.5% decline year over year, attributed to Medicaid attrition [3] - The reported membership figure fell short of the Zacks Consensus Estimate of 46.2 million [3] Segment Performance - Health Benefits segment revenues totaled $41.4 billion, an 11.2% year-over-year increase, beating estimates [6] - Carelon segment revenues reached $16.7 billion, a 38% increase year over year, driven by acquisitions and product revenue growth [7] - Corporate & Other segment reported revenues of $165 million with an operating loss of $140 million, wider than the previous year's loss [9] Financial Position - Cash and cash equivalents were $7.5 billion, down from $8.3 billion at the end of 2024 [10] - Total assets increased to $119.7 billion from $116.9 billion at the end of 2024 [10] - Long-term debt decreased to $28.1 billion from $29.2 billion [11] - Total equity grew to $42.6 billion from $41.4 billion at the end of 2024 [11] Capital Deployment - The company repurchased shares worth $880 million in Q1 2025, with $8.4 billion remaining under its buyback authorization [12] - A quarterly dividend of $1.71 per share was paid, totaling $386 million [12] 2025 Outlook - The company reaffirmed adjusted EPS guidance between $34.15 and $34.85, an increase from the 2024 figure of $33.04 [13] - Operating revenues are expected to grow in the high-single to low-double digits from $175.2 billion in 2024 [15] - Medical enrollment is forecasted to be between 45.8 and 46.7 million in 2025 [15]

Core Insights - Elevance Health reported $48.77 billion in revenue for Q1 2025, a year-over-year increase of 15.4% and a surprise of +5.95% over the Zacks Consensus Estimate of $46.03 billion [1] - The EPS for the same period was $11.97, compared to $10.64 a year ago, with an EPS surprise of +6.78% against the consensus estimate of $11.21 [1] Revenue and Membership Metrics - Total Medical Membership stood at 45.83 million, slightly below the estimated 46.24 million [4] - Medicaid Medical Membership was 8.86 million, close to the estimate of 8.89 million [4] - Medicare Medical Membership was 876 thousand, exceeding the estimate of 866.49 thousand [4] - Commercial Risk-Based Medical Membership was 3.64 million, below the estimate of 3.75 million [4] Revenue Breakdown - Premium revenues reached $40.89 billion, surpassing the average estimate of $38.70 billion, reflecting a year-over-year change of +14.5% [4] - Service fees totaled $2.07 billion, slightly below the estimate of $2.13 billion, showing a -0.4% change year-over-year [4] - Net investment income was $590 million, exceeding the estimate of $461.32 million, with a year-over-year increase of +26.9% [4] - Product revenue was $5.81 billion, above the estimate of $5.11 billion, representing a +29.1% change year-over-year [4] Operating Revenue Performance - Total operating revenue from Carelon Services was $6.54 billion, exceeding the estimate of $5.87 billion, with a year-over-year change of +63% [4] - CarelonRx generated $10.12 billion in operating revenue, surpassing the estimate of $9.40 billion, reflecting a +25.4% change year-over-year [4] - Health Benefits operating revenue was $41.43 billion, above the estimate of $39.82 billion, with a year-over-year increase of +11.2% [4] - Carelon's total operating revenue was $16.65 billion, exceeding the estimate of $15.27 billion, representing a +37.9% change year-over-year [4]

Core Viewpoint - The Cigna Group Foundation is committing $1 million over the next two years to support youth mental health initiatives through Boys & Girls Clubs of America [1][2][6] Group 1: Funding and Initiatives - The funding will be used to train staff at local Clubs to identify signs of youth in distress and implement trauma-informed practices [2][5] - The Cigna Group Foundation previously provided a $250,000 grant to support youth mental health programming and the development of a teen mental health guide [3][6] - The Cigna Group's overall initiative aims to invest more than $27 million in grants to nonprofit organizations by 2026, focusing on youth mental health, veteran mental health, and health equity [6] Group 2: Community Engagement - The partnership with Boys & Girls Clubs of America has enabled over 1,250 employees of The Cigna Group to engage in local activities [3] - A recent event, the "Bright Futures Carnival," was organized in collaboration with basketball legend Earvin "Magic" Johnson to support children affected by wildfires [4] Group 3: Organizational Background - The Cigna Group is a global health company with over 186 million customer relationships and operations in more than 30 countries [7] - Boys & Girls Clubs of America has been providing safe spaces for youth for over 160 years, serving more than 3 million young people through its programs [10]

Financial Data and Key Metrics Changes - GAAP diluted earnings per share was $9.61 and adjusted diluted earnings per share was $11.97, reflecting year-over-year growth of more than 10% [18] - Operating revenue in the quarter was $48.8 billion, an increase of over 15%, driven by higher premium yields in the Health Benefits segment and growth in Medicare Advantage and individual ACA membership [19] - The consolidated benefit expense ratio was 86.4%, an increase of 80 basis points year-over-year, primarily due to higher cost trends in the Medicaid business [20] Business Line Data and Key Metrics Changes - Health Benefits operating gain was $2.2 billion, slightly declining due to higher Medicaid costs, partially offset by operating efficiencies [20] - Calon's operating gain grew 34% to $1.1 billion, driven by growth in pharmacy volumes and improved performance of deployed risk-based capabilities [21] - The company ended the quarter with 45.8 million medical members, up 99,000 from year-end, primarily driven by targeted expansion and better-than-expected retention rates in Medicare Advantage [18] Market Data and Key Metrics Changes - Individual ACA membership grew approximately 11% sequentially, but a moderation in membership is anticipated during the second quarter due to lower-than-expected effectuation rates [18] - In Medicaid, progress on rate alignment is ongoing, with April adjustments coming in as expected and discussions for the July cohort underway [12] - The company is expanding its value-based oncology care model to Medicare Advantage, following success in the commercial segment [10] Company Strategy and Development Direction - The company is focused on advancing its purpose to improve the health of humanity through investments in patient advocacy solutions and digital platforms [7][9] - Elevance Health is expanding its integrated offerings, which combine advocacy, behavioral health, pharmacy, and specialty care, to enhance employer engagement [14] - The acquisition of CareBridge strengthens the company's capabilities in home and community-based services, supporting its whole health approach [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for Medicare Advantage, citing strong retention and disciplined growth strategies [13] - The company is monitoring trends closely, particularly in Medicare costs, which remain elevated but manageable [28] - Management reiterated guidance for adjusted diluted earnings per share to be in the range of $34.15 to $34.85, with expectations for more than 60% of earnings to be realized in the first half of the year [24] Other Important Information - The company was recognized as one of Fortune's 100 best companies to work for and included in the Just 100 by Just Capital, reflecting its commitment to values and impact [17] - The debt to capital ratio was approximately 41%, preserving flexibility for strategic investments [21] Q&A Session Summary Question: Medicare Advantage trends and IRA impact - Management indicated that Medicare costs remain elevated but manageable, with no material changes to prior expectations [27][28] Question: Growth in Carillon services and cross-sales - Carillon services experienced over 60% growth, with strong internal and external expansion noted [35][36] Question: Effectuation rates and membership expectations - Effectuation rates are tracking lower than initial expectations, with projected membership attrition in the mid-single-digit percent range in early Q2 [42] Question: Medicaid MLR margin trends - Medicaid trends remain elevated but decelerated as expected, with stabilization anticipated in the latter half of the year [92] Question: Part D utilization and new normal - Management is comfortable with the mix of Medicare Advantage membership and has not observed substantial variation in Part D utilization [112]